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ABSTRACT
Background.Vascular access outcomes reported across haemo-
dialysis (HD) trials are numerous, heterogeneous and not al-
ways relevant to patients and clinicians. This study aimed to
identify critically important vascular access outcomes.
Method. Outcomes derived from a systematic review, multi-
disciplinary expert panel and patient input were included in a
multilanguage online survey. Participants rated the absolute im-
portance of outcomes using a 9-point Likert scale (7–9 being
critically important). The relative importance was determined
by a best–worst scale using multinomial logistic regression.
Open text responses were analysed thematically.
Results. The survey was completed by 873 participants [224
(26%) patients/caregivers and 649 (74%) health professionals]
from 58 countries. Vascular access function was considered the
most important outcome (mean score 7.8 for patients and care-
givers/8.5 for health professionals, with 85%/95% rating it criti-
cally important, and top ranked on best–worst scale), followed
by infection (mean 7.4/8.2, 79%/92% rating it critically impor-
tant, second rank on best–worst scale). Health professionals
rated all outcomes of equal or higher importance than patients/
caregivers, except for aneurysms. We identified six themes: ne-
cessity for HD, applicability across vascular access types, fre-
quency and severity of debilitation, minimizing the risk of hos-
pitalization and death, optimizing technical competence and
adherence to best practice and direct impact on appearance and
lifestyle.
VC The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. 1
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Conclusions. Vascular access function was the most critically
important outcome among patients/caregivers and health pro-
fessionals. Consistent reporting of this outcome across trials in
HD will strengthen their value in supporting vascular access
practice and shared decision making in patients requiring HD.
Keywords: core outcome set, haemodialysis, outcome, survey,
vascular access
INTRODUCTION
Vascular access complications such as infection, vascular access
failure, cannulation problems and bleeding are associated with
increased morbidity, mortality and health-related costs [1, 2]
and are a major stressor for patients receiving haemodialysis
(HD) [3–5]. Despite increasing numbers of trials in this area,
their implementation into clinical practice is limited by highly
variable, often selectively reported outcomes, which may be of
little relevance to patients and health professionals [6]. In a re-
cent analysis of 168 contemporary HD trials, 23 different vascu-
lar access outcomes were reported and assessed by >1400
different measures [7], thereby limiting comparisons of findings
across trials [8, 9]. Furthermore, vascular access outcomes iden-
tified as highly relevant to patients, such as pain and bleeding
[3, 5], were reported in <15% of HD trials [7], which can limit
decision making.
Consensus-based core outcome sets can help to improve
consistent reporting of outcomes that are critically important to
patients and health professionals [10–12]. Core outcome sets
are defined as ‘an agreed standardised set of outcomes that
should be measured and reported, as a minimum, in all clinical
trials in specific areas of health or healthcare’ [13]. The
Standardized Outcomes in Nephrology – Hemodialysis
(SONG-HD) initiative aims to identify core outcomes that are
critically important to patients and health professionals.
Through an international, multiphase consensus process in-
volving >1300 patients, caregivers and health professionals
from>70 countries, vascular access complications, fatigue, car-
diovascular disease and mortality were established as core out-
come domains for HD [14–16]. This study aimed to identify
the most critically important vascular access outcome based on
the priorities of patients, caregivers and health professionals
and the reasons for their priorities [16]. This will inform the de-
velopment of a standardized core outcome measure for vascular
access to be reported in all HD trials.
MATERIALS AND METHODS
Study design
This open international survey (Supplementary data, Item
S1) assessed the absolute and relative importance of vascular ac-
cess outcomes. It was administered online and available in
English, Malay, Chinese and Spanish. The survey design and
process are shown in Supplementary data, Figure S1. The
Checklist for Reporting Results of Internet E-Surveys was used
for study reporting [17].
Participant selection and recruitment
Participants 18 years of age, including patients, caregivers/
family members, nephrologists, general physicians, radiologists,
surgeons, nurses, physiotherapists, social workers, psycholo-
gists, dietitians, pharmacists, policymakers, researchers and in-
dustry representatives with an interest or experience in HD and
vascular access, were invited to complete this survey. Multiple
recruitment strategies were used to be broadly inclusive.
Patients and caregivers were invited via the SONG database
and patient organizations worldwide (Supplementary data,
Item S2) using an opt-in snowball sampling, which included
the use of social media. Health professionals were recruited via
professional organizations (Supplementary data, Item S2) using
standardized e-mail invitations to membership lists, investiga-
tor networks and via the SONG database. Participants regis-
tered their e-mail on the SONG website to receive an e-mail
invitation with the survey link. All participants provided in-
formed voluntary consent. The study was approved by the
ethics board of the University of Sydney (2015-228).
Data collection
The 12 outcomes included in the survey were identified
from a systematic review of vascular access outcomes reported
in clinical trials [7] and qualitative research [18, 19] and dis-
cussed with the SONG Vascular Access Expert working group
[20]. Outcomes were accompanied by a plain-language defini-
tion (Box 1). The English survey was translated into Malay,
Chinese and Spanish by a bilingual health professional and
cross-checked by a second bilingual health professional to en-
sure accuracy. The survey was custom programmed and tested
for usability and technical functionality prior to being piloted
among 10 participants for every language included (5 patients
and 5 health professionals).
Participants rated the ‘absolute’ importance of each of the 12
outcomes based on a 9-point Likert scale. A score of 7–9 indi-
cated that the outcome was of ‘critical importance’, 4–6 indi-
cated ‘important but not critical’ and 1–3 indicated ‘limited
importance’. An ‘unsure’ option was available. For each out-
come, participants had the option to enter comments about
their choices. Participants could also suggest new outcomes that
were not included in the survey. The ‘relative’ importance of the
12 outcomes was assessed on a best–worst scale, whereby par-
ticipants were presented with five blocks consisting of 6 of the
12 possible outcomes, randomly selected and ordered. For each
block, participants were required to choose the most and the
least important outcome. Like discrete choice experiments, the
best–worst scale is a preference elicitation method that involves
less cognitive burden and provides better discrimination and
greater information retrieval [21–23]. The survey was com-
pleted using LimeSurvey fromOctober 2016 to July 2017.
Data analysis
The absolute importance of each outcome was assessed by
the mean, median and proportion of participants who rated the
outcome as critically important (scores of 7–9) on the Likert
scale. The relative importance was estimated using a multino-
mial logistic regression model. Utility functions containing all
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outcomes and interaction terms for participant characteristics
were constructed for the best–worst choice task. Following this
approach, the mean regression coefficients are the relative im-
portance scores for each outcome [23]. As the regression coeffi-
cients have the same underlying scale, preference scores can be
adjusted to any convenient scale to aid interpretation. Absolute
importance scores were calculated separately for patients/care-
givers and health professionals, whereas relative importance
scores were calculated using interaction terms in the regression
model. Mean differences and 95% confidence intervals (CIs)
were calculated for absolute (Likert) and relative (Best–Worst
scale). Analyses were stratified by participant group (patients/
caregivers and health professionals) to ensure equal weighting.
Complete survey responses for the Likert scale and best–worst
scale, respectively, were analysed. Stata/SE version 14.0
(StataCorp, College Station, TX, USA) and NLOGIT 6
(Econometric Software, Plainview, NY, USA) were used to ana-
lyse the data. Excel (version 16.0; Microsoft, Redmond, WA,
USA) and HyperRESEARCH (version 3.7; ResearchWare,
Randolph, MA, USA) were used to code the text and induc-
tively identify themes focusing on reasons for outcome ratings.
Definition of consensus for the core outcome. The core
outcome was defined as the outcome with the highest absolute
and relative importance scores on the Likert and best–worst
scales in both stakeholder groups. A priori cut-off points were
not possible because of the unknown distribution of scores.
RESULTS
Participant characteristics
Overall, 984 participants commenced the survey, 956 pro-
vided demographic details, 873 completed rating each outcome
on a Likert scale and 828 also completed the best–worst scale
ratings (87% completion rate). Characteristics of included par-
ticipants are shown in Table 1 for patients [n¼ 196 (22%)] and
caregivers [n¼ 28 (4%)] and Table 2 for health professionals
[n¼ 649; (74%)].
Patients/caregivers were from 16 countries. Most patients
had an arteriovenous fistula (AVF) or central venous catheter
(CVC) as their current (62% AVF and 8% CVC) and/or previ-
ous vascular access (54% AVF and 32% CVC) and the most
commonly experienced vascular access complications were can-
nulation problems (40%) and pain (40%). Most patients had
been on HD for <12months (47%). Health professionals in-
cluded 341 (53%) nephrologists, 184 (28%) nurses, 25 (4%) gen-
eral physicians, 17 (3%) surgeons and 82 (12%) stakeholders in
other roles from 56 countries.
Absolute importance of outcomes
Table 3 shows the absolute importance scores. Both
patients/caregivers and health professionals considered func-
tion as the most critically important outcome for vascular ac-
cess (Figure 1). Based on mean scores, the three outcomes rated
the highest by patients/caregivers were function (mean 7.8), in-
fection (7.4) and aneurysms (7.2). The top three outcomes for
health professionals were function (8.5), infection (8.2) and
maturation (7.4). Patients/caregivers and health professionals
considered vascular access appearance as the least important
outcome (mean score 5.2 and 5.4, respectively). Additional out-
comes suggested by survey participants are provided in
Supplementary data, Table S1. None of these new outcomes
were suggested by>1% of all participants.
Relative importance of outcomes
Patients/caregivers and health professionals ranked function
highest among the 12 outcomes (mean best–worst scale scores
6.3 and 9, respectively), followed by infection (mean 5.6 and
7.7, respectively; Table 3 and Figure 2). Patients and caregivers
ranked aneurysms third followed by cannulation problems,
steal syndrome and hospitalization. Health professionals
ranked hospitalization third followed by steal syndrome, can-
nulation problems and maturation.
Differences between stakeholder groups
Differences in mean rating scores between stakeholder
groups are shown in Figure 3. Compared with patients and
caregivers, health professionals rated the following eight out-
comes higher on the Likert scale: maturation [mean difference
1.23 (95% CI 0.95–1.51)], steal syndrome [0.89 (95% CI 0.62–
1.16)], hospitalization [0.83 (95% CI 0.54–1.12)], infection
[0.79 (95% CI 0.55–1.03)], function [0.67 (95% CI 0.45–0.89)],
bleeding [0.63 (95% CI 0.34–0.92)], pain [0.57 (95% CI 0.26–
0.87)] and cannulation problems [0.31 (95% CI 0.03–0.59)].
Mean differences between relative importance scores from the
best–worst scale outlined clearer differences between the two
stakeholder groups (Figure 3), particularly for function [mean
difference 2.67 (95% CI 2.40–2.93)], hospitalization [2.37 (95%
CI 2.09–2.65)], maturation [2.37 (95% CI 2.09–2.64)] and infec-
tion [2.11, (95% CI 1.85–2.38)]. The only outcome that
patients/caregivers rated higher on the best–worst scale com-
pared with health professionals was aneurysm/pseudoaneurysm
[mean difference 0.59 (95% CI 0.36–0.81)].
Differences by language groups
Surveys were completed in English (n¼ 518), Chinese
(n¼ 191), Malay (n¼ 131) and Spanish (n¼ 33). Overall, im-
portance ratings were similar across all four languages and
function and infection were consistently considered the two
most important outcomes (Supplementary data, Figures S2 and
S3).
Themes. Based on comments from both stakeholder groups,
we identified six themes that reflected reasons for the rating of
vascular access outcomes: necessity for HD, applicability across
vascular access types, frequency and severity of debilitation,
minimizing the risk of hospitalization and death, optimizing
technical competence and adherence to best practice and direct
impact on appearance and lifestyle. Supporting quotations are
provided in Table 4.
Necessity for HD. Vascular access function was rated critically
important because ‘No access, no dialysis. Poor access, poor di-
alysis’. A functioning vascular access was described as
Survey to prioritize vascular access outcomes 3
D
ow
nloaded from
 https://academ
ic.oup.com
/ndt/advance-article-abstract/doi/10.1093/ndt/gfz148/5542605 by G
hent U
niversity user on 06 April 2020
indispensable for survival and therefore was regarded as a key
issue to address in research and clinical practice.
Applicability across vascular access types. Function was known to
apply to all access types. However, outcomes such as infection
and interference with activities were predominantly viewed as
being more specifically related and relevant to CVC and were
thus regarded to be of lesser importance.
Frequency and severity of debilitation. Certain outcomes, such
as steal syndrome, bleeding and pain, were prioritized
based on the severity and overall frequency of the outcome:
‘Steal [syndrome] is an important complication but it
occurs in <5% of AVF patients. Thus, in relative terms, it is
not as important as the other complications (e.g. primary
failure)’. However, a rare event like steal syndrome was rec-
ognized as a severe complication. Similarly, bleeding was
considered ‘important because a bleeding fistula can lead to
potential mortality and morbidity’, yet was downgraded on
the importance scale in view of the low frequency of
occurrence.
Table 1. Characteristics of patients and caregivers [N ¼ 224 (26%)]
Characteristics n (%) Characteristics n (%)
Participant type Educationa
Patient 196 (88) Did not complete high school 52 (25)
Caregiver/family member 28 (12) High school graduate 29 (14)
Professional certificate/diploma 43 (21)
Gender Undergraduate degree 57 (27)
Male 109 (49) Postgraduate degree 27 (13)
Female 115 (51)
Current type of treatmenta
Age group (years) In-centre HD 74 (36)
18–40 53 (24) Satellite HD 18 (9)
41–50 46 (21) Home HD 37 (18)
51–60 52 (23) Peritoneal dialysis 4 (2)
61–70 60 (27) Transplant 67 (32)
71–80 12 (5) Not applicable 8 (4)
81 1 (<1)
Years on HDa
Marital statusa <1 85 (47)
Single 43 (21) 1–5 38 (21)
Partner/de facto 7 (3) 6–10 12 (7)
Married 125 (60) 11–15 11 (6)
Divorced/separated/widowed 33 (16) >15 14 (8)
Not applicable 19 (11)
Number of childrena
0 85 (41) Current vascular accessa
1–2 89 (43) AVF 129 (62)
3–4 31 (15) AVG 6 (3)
5 2 (1) CVC 16 (8)
Not applicable 57 (27)
Employment statusa
Employed (full time/part time) 80 (39) Previous vascular access
Unemployed 35 (17) AVF 111 (54)
Retired 71 (34) AVG 13 (6)
Student 2 (1) CVC 67 (32)
Other 19 (9) Not applicable 16 (8)
Country Experienced vascular access complicationsa
Australia 49 (22) Bleeding 77 (37)
USA 36 (16) Hospitalization 42 (20)
China 35 (16) Infection 29 (14)
Malaysia 32 (14) Needling problems 83 (40)
UK 23 (10) Pain 83 (40)
Canada 14 (6) Dysfunction 72 (35)
New Zealand 12 (5)
Otherb 23 (10) Current type of treatmenta
In-centre HD 74 (36)
Satellite HD 18 (9)
Home HD 37 (18)
aTotal numbers do not add up to the total number of participants due to undisclosed responses (excluded).
bOther includes nine countries (in descending order of frequency): Brazil, Denmark, South Africa, India, Ireland, Spain, Cuba, Greece and The Netherlands.
AVG, arteriovenous graft; AVF, arteriovenous fistula; CVC, central venous catheter; HD, haemodialysis.
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Minimizing the risk of hospitalization and death. Outcomes, includ-
ing vascular access dysfunction, infection, aneurysm, bleeding
and steal syndrome, were prioritized highly if they were
expected to increase the risks of death, need for interventions
and hospitalization.
Optimizing technical competence and adherence to best practice.
Participants believed that consistent demonstration of tech-
nical competence, adherence to best practice and ability to
optimize technique skills could help mitigate avoidable com-
plications related to maturation, cannulation or aneurysm
formation. Cannulation problems were closely related to the
‘competency/skill level of the cannulation technician’s.
Infections were considered avoidable with adherence to good
clinical practice. Achieving consensus on the optimal timing
of first cannulation of a mature/maturing vascular access to
improve maturation and ensuring implementation of proto-
cols for sterile handling of vascular accesses to minimize in-
fection risks were highlighted as two important research
priorities.
Direct impact on appearance and lifestyle. Some participants gave
higher priority to outcomes that had a palpable and severe im-
pact on their personal identity, self-esteem, independence and
daily life. For example, appearance was considered least impor-
tant overall, however, this outcome was ranked highly by
patients who viewed the vascular access as ‘ugly’ and ‘unpleas-
ant’ and by patients who had been asked if they were victims of
domestic abuse due to bruising and scarring. Cannulation prob-
lems were viewed as critically important for home dialysis train-
ing units, because the inability to cannulate the arteriovenous
access by patients or their family members was identified as a
limiting step to dialysing independently at home.
DISCUSSION
The most critically important vascular access outcome identi-
fied by patients/caregivers and health professionals was vascular
access ‘function’. This finding was consistent across the two
groups, whether measured as absolute or relative importance.
Participants identified the necessity of a functioning vascular
Table 2. Characteristics of health professionals [N ¼ 649 (74%)]
Characteristics n (%) Characteristics n (%)
Participant type Number of trials as investigatora
Nephrologists 341 (53) 0 147 (33)
Nurses 184 (28) 1–5 169 (38)
General physicians 25 (4) 6–10 45 (10)
Surgeons 17 (3) 11–15 9 (2)
Trainees 16 (2) 16 27 (6)
Social worker 4 (1) Not applicable 49 (11)
Radiologist 2 (<1)
Psychologists 2 (<1) Other rolesa
Dietitian 3 (<1) Government, policy 58 (13)
Researcher 15 (2) CPG 140 (31)
Pharmacist 1 (<1) Funding 32 (7)
Policy maker 2 (<1)
Industry/private sector 7 (1) Country
Other 47 (7) China 159 (25)
Malaysia 109 (17)
Gender Australia 88 (14)
Male 293 (45) Spain 27 (4)
Female 356 (55) Canada 27 (4)
UK 26 (4)
Age group (years) USA 24 (4)
18–40 268 (41) Portugal 18 (3)
41–50 198 (31) India 15 (2)
51–60 138 (21) Brazil 14 (2)
61–70 38 (6) New Zealand 10 (2)
71–80 6 (1) The Netherlands 9 (1)
81 1 (<1) Italy 9 (1)
Belgium 8 (1)
Experience with HD (years)a Otherb 106 (16)
<11 166 (37)
11–20 146 (33)
21–30 76 (17)
>30 40 (9)
Not applicable 18 (4)
aTotal numbers do not add up to the total number of participants due to undisclosed responses (excluded).
bOther includes 42 countries (in descending order of frequency): Uruguay, Saudi Arabia, Greece, France, Romania, Poland, Peru, Germany, Egypt, Colombia, Argentina, Sweden,
Chile, Bolivia, Turkey, Slovenia, Singapore, Serbia, Russian Federation, Montenegro, Mexico, Lithuania, Israel, Ireland, Croatia, Austria, Vietnam, Syria, Switzerland, Sri Lanka, South
Africa, Rwanda, Philippines, Paraguay, Nigeria, Morocco, Kosovo, Hungary, Finland, El Salvador, Bulgaria and Belarus.
CPG, Clinical Practice Guidelines.
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Table 3. Summary of importance scores for patients/caregivers and health professionals
Outcomes Likert score,
median (IQR)
Likert score,
mean (95% CI)
Proportion critically
important (7–9) (%)
BWS score,
mean (95% CI)
Patients/caregivers HP Patients/caregivers HP Patients/caregivers HP Patients/caregivers HP
Vascular access functiona 9 (7–9) 9 (7–9) 7.8 (7.6–8.0) 8.5 (8.5–8.6) 85 95 6.3 (5.9–6.8) 9.0 (8.6–9.4)
Infection 8 (7–9) 8 (7–9) 7.4 (7.2–7.6) 8.2 (8.1–8.3) 79 92 5.6 (5.2–6.0) 7.7 (7.3–8.0)
(Pseudo-)aneurysm 8 (7–9) 7 (6–8) 7.2 (7.1–7.3) 7.4 (7.2–7.6) 78 70 5.3 (4.9–5.7) 4.7 (4.4–4.9)
Cannulation problems 7 (6–8) 7 (6–8) 6.8 (6.6–7.1) 7.1 (7.0–7.3) 67 69 4.6 (4.2–5.0) 5.9 (5.6–6.2)
Steal syndrome 7 (5–9) 8 (7–9) 6.7 (6.4–6.9) 7.6 (7.4–7.7) 61 80 4.6 (4.2–5.0) 6.0 (5.7–6.2)
Hospitalization 7 (5–9) 8 (7–9) 6.6 (6.4–6.9) 7.4 (7.3–7.6) 63 76 4.1 (3.2–4.5) 6.5 (6.2–6.8)
Oedema 7 (5–8) 7 (6–8) 6.5 (6.2–6.7) 6.7 (6.6–6.9) 57 55 3.2 (2.9–3.5) 4.0 (3.8–4.3)
Maturation 7 (5–9) 8 (7–9) 6.4 (6.2–6.7) 7.7 (7.5–7.8) 56 79 2.7 (2.8–3.5) 5.1 (3.5–4.0)
Bleeding 7 (5–8) 5 (7–8) 6.3 (6.1–6.6) 7.0 (6.8–7.1) 52 65 3.1 (2.4–3.7) 3.8 (2.9–3.6)
Interference with activities 6 (4–8) 6 (5–7) 5.9 (5.7–6.2) 6.2 (6.0–6.3) 40 45 1.9 (2.3–3.2) 2.5 (4.8–5.4)
Pain 6 (4–8) 7 (5–8) 5.9 (5.6–6.1) 6.4 (6.3–6.6) 42 51 3.1 (1.4–2.3) 3.2 (2.2–2.7)
Appearance 5 (4–8) 5 (4–6) 5.2 (5.1–5.4) 5.4 (5.1–5.6) 33 24 1 (ref) 1 (ref)
aCore outcome (i.e. most critically important outcome) based on highest absolute and relative importance scores in both stakeholder groups (i.e. patient/caregiver and health
professionals).
BWS, best–worst scale; HP, health professionals; IQR, interquartile range.
FIGURE 1: Proportion of patients/caregivers (right) and health professionals (left) considering outcomes as critically important, important or
of limited importance. Critically important (black): 7–9 points on Likert scale; important (dark grey): 4–6 points on Likert scale; limited impor-
tance (light grey): 1–3 points on Likert scale.
FIGURE 2: Mean relative importance scores of patients (light grey) and health professionals (dark grey) based on the BWS. Ordered by the
mean importance scores of patients/caregivers (bars with 95% CIs). BWS, best–worst scale.
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access to provide adequate dialysis and the devastating and
costly consequences of a failing vascular access, including inva-
sive procedures, hospitalizations and death, as important rea-
sons for prioritizing this outcome. The second highest-ranking
outcome, vascular access-related infection was deemed critically
important because of the detrimental consequences of pro-
longed hospitalization and associated increased morbidity and
mortality. Infection was considered as largely preventable
through best clinical practice and to be mostly a consequence of
CVC use. It was deemed not as relevant to all forms of vascular
access, whereas function was equally applicable to all vascular
access types. While there was consensus on function and infec-
tion as the most critically important outcomes across both
stakeholder groups, patients and caregivers considered aneur-
ysms to be more important and health professionals particu-
larly viewed maturation, steal syndrome and hospitalizations to
be of greater importance.
Concordant with our findings, problems with vascular ac-
cess function have been voiced as the most prominent concern
by HD patients. In a survey of 128 patients from a single US di-
alysis programme, 59% reported vascular access thrombosis as
their major concern [5]. A survey administered to 132 HD
patients in Canada identified that within the dialysis complica-
tions domain, concerns regarding vascular access longevity
caused the highest level of dissatisfaction [24]. An international
study with patients and different health professional groups on
priorities for guidelines regarding vascular access found that
decisions related to vascular access type and site selection and
prevention of infections were the highest priorities to be
addressed. However, while patients’ highest priority was how to
manage catheter thrombosis, nephrologists, nurses and sur-
geons/radiologists considered the management of arteriovenous
access stenosis and central vein obstruction within their top 10
priorities to be covered by international guidelines [25].
Aligned with patients’ concerns, vascular access function has
been a major focus of HD trials. In a systematic review of 168
contemporary randomized trials in HD, function was the most
frequently reported vascular access outcome (81% of trials) fol-
lowed by infection (38%), yet function was the most heteroge-
neous outcome and measured in nearly 500 different ways [7].
Based on this review, the uptake of standardized outcome defi-
nitions has been minimal. Less than 13% of trials published or
registered between 2011 and 2016 used standardized definitions
to measure vascular access patency and only 22% of trials used
standardized definitions to assess vascular access–related infec-
tions [7]. These findings underpin the need for broader imple-
mentation of internationally agreed and standardized patient-
important outcome measures to enhance the consistency and
relevance of outcome reporting in clinical trials and beyond.
Recently the Kidney Health Initiative (KHI) published a series
of papers on recommended trial endpoint definitions tailored
to the different types of vascular access and time points of their
life cycle to facilitate the development of effective
interventions and products to improve vascular access
FIGURE 3: Difference in absolute (Likert) and relative (BWS) mean scores between patients/caregivers and health professionals. Error bars
refer to 95% CI. BWS, best–worst scale (assessment of the relative importance of outcomes); Likert, Likert scale (assessment of the absolute im-
portance of outcomes).
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Table 4. Themes with selected illustrative quotations
Themes with illustrative quotations Outcome Likert score
Necessity for HD
‘No access, no dialysis. Poor access, poor dialysis’. (Health professional) Function 9
‘Without vascular access that works effectively, patients could either get a less than adequate dialysis
dose or have to spend more time on dialysis’. (Health professional)
Function 9
‘Without vascular access there is no hemo!’ (Health professional) Function 9
‘Vascular function ¼ patient’s life. There is no doubt that any problems related to blood vessels should
be regarded as a key issue’. (Patient)
Function 9
Applicability across vascular access types
‘Depends on kind of vascular access. . .per example catheter versus native AVF’. (Health professional) Infection 7
Not applicable as neckline used. (Caregiver) Pain NA
‘This would relate more to tunnelled CVC than AVF I would think. (Health professional) Interference with activities 7
Weak evidence that arteriovenous accesses are superior to CVC; therefore, maturation of an arteriove-
nous access should not be the first question to ask’. (Health professional)
Maturation 1
Frequency and severity of debilitation
‘Although rare, this might be a cause for giving up to that access’. (Health professional) Steal syndrome 7
‘Experienced a number periods of hospitalisation due to failed fistulas and emergency measures taken
(e.g. a temporary line in the groin) to ensure haemodialysis could continue to be performed at sched-
uled times’. (Patient)
Hospitalization 7
‘Frequent in the beginning but usually no patient complains after some weeks or months’. (Health
professional)
Pain 3
‘I applied a cream to my site before needling so did not feel any pain’. (Patient) Pain 7
‘Importance would depend on the frequency and severity of the bleeding’. (Health professional) Bleeding 6
‘No significant problems with bleeding, just odd occasions of incidents when either I or my carer were a
little too impatient when removing the needle at the end of the session’. (Patient)
Bleeding 6
‘Infective complications in my country is very high’. (Health professional) Infection 8
‘Most of my haemodialysis related complications are related to vascular access’. (Health professional) Hospitalization 9
‘Occurs 1–3/year/patient and lasts 1–2 weeks; cumbersome in practice!’ (Health professional) Bleeding 8
‘The needling process was my regular nightmare, even after the addition of using an anesthetic injection
it was still a treatment that had me in tears. When I had a catheter pre a fistula I had painful episodes of
machine alarming, blockage, nausea’. (Patient)
Pain 9
‘Steal can be really distressing and it seems very unfair to add this to all the other complications of a di-
alysis patient’s life’. (Health professional)
Steal syndrome 9
‘Steal is an important complication but it occurs in less than 5% of AVF patients. Thus, in relative
terms, it is not as important as the other complications (e.g. primary failure)’. (Health professional)
Steal syndrome 4
‘This is the most common reason why our patients are admitted to my hospital . . . vascular access pa-
tency is a thorny issue’. (Health professional)
Function 9
‘Very important if you get it, but fortunately true steal syndrome is uncommon’. (Health professional) Steal syndrome 5
‘When/if this happens it is very, very painful’. (Patient) Aneurysm 7
Minimizing the risk of hospitalisation and death
‘A serious problem in patients with long standing in dialysis that needs a rapid solution Function 9
Frequently, the patient will need some intervention over the fistula, or even closing it. It’s very impor-
tant’. (Health professional)
Steal syndrome 8
‘It is a cause of death and has to be prevented by careful disinfection and handling’. (Health
professional)
Infection 6
‘In the meanwhile, the patient will need a catheter, and this fact increases the risk of infection, hospital-
isation, etc. Good vascular access function is critical’. (Health professional)
Function 9
‘Infection can be life-threatening’. (Health professional) Infection 9
‘Important because a bleeding fistula can lead to potential mortality and morbidity e.g. insertion of line
with associated sepsis risks’. (Health professional)
Bleeding 6
‘This is very important not just because of the morbidity and mortality to the patients, but also because
of the burden that infection, particularly of temporary [vascular] access, puts on us for hospital beds
and other resources’. (Health professional)
Infection 9
‘We had 2 patients who died because of this’. (Health professional) Aneurysm 8
‘The weakening of the blood vessel wall is definitely a dangerous situation for the patient, and there
may be many reasons for this situation and the consequences are severe’. (Patient)
Aneurysm 8
‘This problem should be prioritised, it affects patients’ life’. (Patient) Infection 9
Optimizing technical competence and adherence to best practice
‘Ensuring that the effort that goes into creating an AVF results in a working access is really important. I
expect some units have better records than ours and I would love to know why’. (Health professional)
Maturation 6
‘This can be a problem sometimes due to the competency/skill level of cannulation technicians’.
(Patient)
Cannulation problems 9
‘We need a consensus in time to maturation, needles to use, etc. tackle the maturation time with the
same approach in every dialysis units’. (Patient)
Maturation 9
Infection 9
Continued
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outcomes [26–29]. Complementing this work by the KHI, the
inclusion of vascular access function as part of the core outcome
set for HD established through the international SONG initia-
tive will help to ensure more consistent reporting of outcomes
in HD research that are considered important by all relevant
stakeholders [16, 30]. A core outcome measure for vascular ac-
cess function applicable to all three access types is currently be-
ing established, piloted and validated by the SONG initiative to
facilitate global implementation in research and clinical
practice.
Increasingly, clinical performance measures have been
used for quality improvement for enhanced transparency
through public reporting and calculating service payments.
The clinical performance measures for end-stage kidney dis-
ease used by the Centers for Medicare and Medicaid Services
include mortality, hospital readmissions, patient experience
of care, dialysis adequacy, vascular access type in use, blood
transfusions, bloodstream infections and hypercalcaemia
[31]. Clinical performance measures are a powerful tool for
quality improvement and have become a driving force to de-
termine care delivery. However, current clinical performance
measures are largely chosen by health professionals and may
not reflect what patients care most about. Adding core out-
comes that are considered critically important by patients,
caregivers and health professionals, like vascular access func-
tion, may help improve the relevance of performance-based
measures to patients. For example, monitoring the rate of
vascular access interventions needed to maintain its use for
HD as a measure of function rather than targeting a
percentage of AVF and CVC use may be recommended.
This is a more patient-centred goal of finding the optimal
vascular access requiring the fewest number of procedures to
provide adequate dialysis [32, 33]. Incentivizing a reduction
in interventions is anticipated to reduce health care costs
and hospitalizations while simultaneously reducing the bur-
den of invasive, often painful and anxiety-provoking proce-
dures that are disruptive to patients’ lives [3, 34].
Vascular access infection was the second most important
outcome identified by patients/caregivers and health professio-
nals. Infections are an important cause of morbidity and death
in HD patients [2, 35, 36]. Approximately 30% of patients using
a CVC experience a bloodstream infection per year and each
episode costs the health care system US$17 000–32 000 [37].
However, infection is less relevant to vascular access problems
as a whole, because it primarily relates to CVC use with a mini-
mum 9-fold higher rate of access-related bloodstream infections
compared with AVF use [8, 38]. Survey participants empha-
sized that infection is preventable if there is strict adherence to
best practice guidelines. A Centers for Disease Control and
Prevention evidence-based quality improvement project across
17 HD facilities confirmed that staff training and competence
assessment, aseptic technique, chlorhexidine use for CVC exit
site care and staff performance feedback can reduce access-
related bloodstream infections by 54% [39]. For these and other
reasons, infection was deemed less suitable as a core outcome
compared with function [34].
Patients/caregivers rated the importance of aneurysms/
pseudoaneurysms third and significantly higher compared
Table 4. Continued
Themes with illustrative quotations Outcome Likert score
‘We need to apply sterile protocols during manipulation of vascular access, in every dialysis units
worldwide, in for profit and no-profit centres’. (Patient)
‘Perhaps the only way to solve this problem is to find a professional key opinion leader surgeon’.
(Patient)
Maturation 3
‘Need staff who are expert at cannulating with needles in the area of the vascular access’. (Patient) Maturation 8
‘It may be a serious problem that may imply the need to close the access but it is avoidable. I do not un-
derstand why the vascular surgeons treat the varicose veins with contention but not the fistulae. All my
patients use an elastic brace on their fistulae’. (Health professional)
Aneurysm 3
‘Suggestion that training for nurses for standardised needling was ignored’. (Patient) Pain 4
‘Important but should be avoidable with good clinical practice. Anything that makes it easier for
patients and staff to minimise the risk of infection would be good’. (Health professional)
Infection 8
‘This should not happen at all, if it does then bad practices are being adopted’. (Patient) Infection 6
Direct impact on appearance and lifestyle
‘Can’t wear my wedding ring do to the change in my hands due to my fistula’. (Patient) Oedema 8
‘Due to the bruising and scarring I’ve been asked many times if my husband has been abusing me’.
(Patient)
Appearance 9
‘I found I was not as active as I was and could not do things I used to do, This I found very frustrating’.
(Patient)
Interference with activities 9
‘This is a very ugly side effect of the fistula and the buzzing is also unpleasant’. (Patient) Appearance 9
‘Mine looks like a Kiwi fruit. Living on a rural property, mowing, chain sawing, gardening etc. Needs a
tie off, but I’m a high chance of rejection’. (Patient)
Appearance 9
‘Women seemed more concerned about this but my experience majority of patients understand that ac-
cess is their lifeline’. (Health professional)
Appearance 7
‘This can be an issue for us as we are primarily a home training unit, with the expectation that patients
or family members will be cannulating the access. Unfortunately, they are training on AVF that are still
maturing’. (Health professional)
Cannulation problem 9
AVF, arteriovenous fistula; CVC, central venous catheter; HD, haemodialysis; NA, not applicable.
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with health professionals. The responses from patients in
our survey and the SONG-HD vascular access consensus
workshop [34] suggest that fear of a catastrophic haemor-
rhage was a key reason for the high importance of this out-
come. Other reasons may include associated pain,
displeasing appearance and physical activity restriction to
mitigate risks like rupture [3, 18].
Cannulation problems were considered an important out-
come that could be overcome by optimizing cannulation skills
and technique. Cannulation technique has a significant impact
on vascular access outcomes. In 2009, a survey conducted
across 171 European HD units revealed that area cannulation
technique, although used in 66% of patients, was associated
with inferior access survival compared with the rope ladder or
buttonhole technique [40]. Compared with rope ladder, the
buttonhole technique is associated with a higher risk of infec-
tion without proven advantages regarding cannulation-
associated pain, vascular access interventions, survival or hae-
matoma and aneurysm formation [41–43]. Quality improve-
ment programmes to guide optimal cannulation practices and
future research evaluating the effectiveness of structured cannu-
lation skill training, remuneration of expert cannulators and
promotion of self-cannulation may help reduce cannulation-
associated problems and resulting concerns for patients [4, 44].
This international survey included a broad group of stake-
holders across 58 countries and a large proportion of patients/
caregivers. Administering the survey in multiple languages
allowed for recruitment from countries, such as China and
Malaysia, that have not been included in previous vascular ac-
cess surveys [4, 18, 25]. The large sample size, coupled with a
quantitative assessment of absolute and relative importance rat-
ings enabled detailed and robust assessment of vascular access
outcomes prioritization. Qualitative data analysis provided fur-
ther insights into the meaning and reasons for outcome prioriti-
zation by survey participants. However, there are some
potential limitations. We used broad recruitment strategies, but
the number of individuals who accessed the survey but did not
continue is unknown, and thus we could not calculate an accu-
rate response rate. We acknowledge that the characteristics of
those who received an invitation to complete the survey but did
not respond to the survey cannot be determined. The survey
was administered online to ensure efficient dissemination and
minimize data transfer errors, which restricted the sampling
frame to computer literate participants with Internet access.
This, together with the administration of the survey in only four
languages, may have led to ascertainment bias (e.g. overrepre-
sentation of nephrologists compared with other health profes-
sional groups). Differences in patient/caregiver experiences
with respect to specific access types and their complications
may have impacted on outcome prioritization. However, these
data were generally not disclosed by survey respondents,
thereby preventing reliable exploratory analysis of this issue.
The survey was restricted to the 12 most commonly reported
outcomes; however, the option to suggest new outcomes en-
sured that additional important outcomes were not missed.
A further limitation inherent to all surveys is the potential for
Box 1. Outcomes and definitions
Outcome Definition
Function The ability to use the vascular access for HD.
Problems with function are difficulties or the inability to use the vascular access for HD because the access is not
working well. This includes poor blood flow because of blood clots or narrowing of vessels, blocked lines (catheters),
needing extra procedures (such as surgery for declotting) to try and get the access to work properly and loss of the
vascular access with the need for a new vascular access.
Maturation Maturation is the time needed for a new fistula or graft to work and be used for HD.
Problems with maturation include the need for a line (catheter) because the fistula or graft is not ready for use or the
need to have further tests (such as ultrasound) and procedures (such as surgery) until the graft or fistula can be used
for HD.
Bleeding Bleeding or bruising where the vascular access is located, immediately before, during or after dialysis or a procedure
(examples include bleeding during needling/cannulation or ongoing bleeding after dialysis for fistulas/grafts or bleed-
ing after a line insertion).
Pain Pain (including fear of pain) at or around where the vascular access is located (e.g. during needling/cannulation or
during or after vascular access procedures).
Infection Disease/harm caused by organisms such as bacteria that enter the body via the vascular access. This includes blood
infection and infection in and around the vascular access.
Reduced blood supply (steal
syndrome)
Pain, tingling, paleness or coolness of the hand or forearm on the side of the vascular access caused by problems with
blood supply. This can also lead to numbness, weakness in finger/hand/forearm, ulcers (dying tissue) or dead (black)
tissue.
Interference with activities Problems with or inability to perform activities you wish to do because of your vascular access, such as bathing,
sports, wheeling a wheelchair, being in an uncomfortable position during dialysis or unable to do something because
of an appointment/procedure for your vascular access.
Weakening of the vessel wall
(aneurysm/pseudo-aneurysm)
A balloon-like swelling in the wall of the vessels of the fistula or graft. This swelling weakens the vessel wall and can
burst/rupture.
Cannulation (needling)
problem
Problems with placing the dialysis needles into the fistula or graft or the need for repeated punctures.
Oedema Swelling of the body part where the vascular access is located (leg, arm, can also extend to neck or face).
Hospitalization The need to be in hospital because of vascular access problems such as infection, procedures or bleeding.
Appearance Changes in appearance because of the vascular access (e.g. bulging veins and scars).
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response bias, including demand bias and neutral or extreme
responses.
In conclusion, ‘function’ was the most critically important
vascular access outcome for patients/caregivers and health pro-
fessionals. The broad applicability of this outcome to all access
types, the absolute necessity of a functioning vascular access to
provide adequate dialysis and the detrimental consequences of
a failing access make this outcome a meaningful and suitable
core outcome. A definition and metric for vascular access func-
tion are currently in development and will be piloted and vali-
dated in an international, multicentre study to ensure it is a
reliable and feasible outcome measure to be used in research
and clinical practice without adding undue burden to research-
ers and health professionals to ensure global implementation
[16, 20, 34]. Consistent reporting of a validated, feasible, robust
and meaningful outcome measure for vascular access function
in research and ultimately in quality improvement projects will
help to inform clinical practice and decision making in a mean-
ingful way.
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